Sutro Biopharma, Inc. (STRO): Cash & Equivalents
$58.13M
As of 2025-12-31
$54.34M
As of 2026-06-30
+7.1%
3-year compound annual growth
-22.4%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $58.13M | -69.5% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $190.30M | +174.7% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $69.27M | +46.6% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $47.25M | +55.4% | 2025-03-13, Balance as of period end |
| 2021-12-31 | $30.41M | -85.2% | 2024-03-25, Balance as of period end |
| 2020-12-31 | $206.15M | n/m | 2023-03-30, Balance as of period end |
| 2019-12-31 | $4.96M | -96.0% | 2022-02-28, Balance as of period end |
| 2018-12-31 | $125.30M | +469.0% | 2021-03-18, Balance as of period end |
| 2017-12-31 | $22.02M | +89.9% | 2020-03-16, Balance as of period end |
| 2016-12-31 | $11.59M | n/a | 2019-04-01, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $58.13M | -69.5% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $61.85M | +5.8% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $88.33M | -38.4% |
| Agenus Inc (AGEN) | 2025-12-31 | $3.00M | -92.6% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $8.48M | -66.1% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $60.24M | -59.7% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $129.88M | -42.1% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $65.93M | -36.4% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $104.13M | -54.2% |
Compare STRO, IPSC, IBRX, AGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗